Please enable JS


5 reasons biosimilars must have distinguishable names

Jul 27/50SN Staff/ GHLF in the news

If you ask patients with severe chronic diseases, such as those with rheumatoid arthritis, cancer, or multiple sclerosis, what they believe is the most important factor in achieving a positive outcome for their condition or disease, the vast majority will say it’s the relationship they have with their physician and treatment team.


Arthritis: A Disease for All Generations

Jul 24/50SN Staff/ Advocates in the news

When Lauren Marchi entered college as a freshman at American University in Washington, DC, she was a classically trained pianist and ballerina. She had aspirations of pursuing degrees in piano performance and marketing while dancing on the side, but early in her senior year she was forced to question her well-laid plans.


Biosimilars for Arthritis Patients: Challenges and Opportunities Summary

Jul 16/50SN Staff/ GHLF Interviews Letters and Testimony

On July 13th, the Global Healthy Living Foundation, working with the Coalition of State Rheumatology Organizations and the Arthritis Foundation, in cooperation with the Congressional Arthritis Caucus, co-hosted a congressional briefing on “Biosimilars for Arthritis Patients: Challenges and Opportunities.”


CDC’s Advisory Committee for Immunization Practices (ACIP) – June Meeting outcome

Jul 16/50SN Staff/ Letters and Testimony

Dr. Neal Raisman, a GHLF advocate who lost his son Isaac to meningitis in 2005, provided testimony before the ACIP, urging the Committee to approve the meningitis B vaccine for routine clinical use.


MedPage Today – Providers, Patients Demand Transparency for Biosimilar Use

Jul 16/50SN Staff/ Advocates in the news

Katherine “Kat” Macfarlane, JD, who has rheumatoid arthritis and inflammatory eye disease, spoke at a briefing held at the House of Representatives on Monday about regulation of biosimilars.